Novan Accounts Receivables 2011-2026 | NOVN

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Novan

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
22 M	4.47 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22 M	4.47 M	13.2 M

Quarterly Accounts Receivables Novan

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
13.8 M	22 M	14.9 M	18.2 M	16 M	4.47 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
22 M	4.47 M	14.9 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Verastem VSTM	8.81 M	$ 5.04	-4.73 %	$ 349 M	USA
Voyager Therapeutics VYGR	1.76 M	$ 3.96	-4.12 %	$ 232 M	USA
VistaGen Therapeutics VTGN	2.8 K	$ 0.57	-5.87 %	$ 17.6 M	USA
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	130 M	-	-	$ 866 M	China
Albireo Pharma ALBO	3.27 M	-	-0.23 %	$ 916 M	USA
Aptinyx APTX	257 K	-	-39.0 %	$ 4.57 M	USA
Arena Pharmaceuticals ARNA	1.65 M	-	-6.81 %	$ 3.04 B	USA
Ayala Pharmaceuticals AYLA	234 K	-	-	$ 7.46 M	Israel
Acorda Therapeutics ACOR	17.3 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	300 K	-	-	$ 546 M	USA
Acasti Pharma ACST	802 K	-	4.01 %	$ 150 M	Canada
Avid Bioservices CDMO	16.6 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	886 K	-	-	$ 86.2 M	USA
Advaxis ADXS	234 K	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	50.4 M	$ 12.41	-11.1 %	$ 1.88 B	USA
Wave Life Sciences Ltd. WVE	1.28 M	$ 6.37	2.66 %	$ 1.07 B	Singapore
Xenetic Biosciences XBIO	3 M	$ 2.72	-2.86 %	$ 4.63 M	USA
XBiotech XBIT	4.11 M	$ 2.27	-1.73 %	$ 69.2 M	USA
Xenon Pharmaceuticals XENE	1.47 M	$ 54.48	-1.89 %	$ 4.24 B	Canada
Xeris Pharmaceuticals XERS	51 M	$ 5.4	-3.05 %	$ 866 M	USA
X4 Pharmaceuticals XFOR	573 K	$ 4.04	-6.26 %	$ 171 M	USA
Xencor XNCR	29.3 M	$ 11.42	-7.23 %	$ 848 M	USA
XOMA Corporation XOMA	4.9 M	$ 30.17	-1.18 %	$ 364 M	USA
BeiGene, Ltd. BGNE	865 M	-	0.49 %	$ 251 B	Cayman-islands
22nd Century Group XXII	3.59 M	$ 2.41	-18.03 %	$ 444 K	USA
BioDelivery Sciences International BDSI	56.9 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	2.76 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	411 K	-	-	$ 3.74 B	USA
Zai Lab Limited ZLAB	106 M	$ 18.0	2.8 %	$ 19.7 B	China
Enlivex Therapeutics Ltd. ENLV	28 K	$ 1.05	-3.67 %	$ 21.5 M	Israel
Enochian Biosciences ENOB	432 K	-	-	$ 40.5 M	USA